Yet, increasing the complexity of combined treatment concepts by adding CD73-targeted immunotherapy will add to the disturbance of pulmonary immune homeostasis and the potential occurrence of overlapping irAEs in NSCLC treatment and also further complicate adequate risk assessment, diagnosis, and therapy of pneumonitis. This evidence concerns the gene NT5E and non-small cell lung carcinoma.